Non-Small-Cell Lung Cancer – Current Treatment – Current Treatment: Physician Insights – Non-Small-Cell Lung Cancer (US)

Immune checkpoint inhibitors continue to anchor the treatment of non-small-cell lung cancer (NSCLC), while rapid advances in biomarker-driven strategies are accelerating patient segmentation and reshaping competitive dynamics. In 2025, the FDA approved six new biomarker-targeted therapies for locally advanced or metastatic NSCLC, five of which were granted accelerated approval. These therapies include Ibtrozi for ROS1-positive NSCLC, Emrelis for NSCLC with high c-Met protein overexpression, Datroway and Zegfrovy for EGFR-mutated NSCLC, and Hernexeos and Hyrnuo for HER2-mutated NSCLC. In parallel, the approval of Keytruda Qlex and Rybrevant Faspro—subcutaneous formulations of Keytruda and Rybrevant—across adult indications, including NSCLC, further reinforces a growing emphasis on treatment convenience alongside efficacy. Collectively, these approvals heighten the competitive density of the market, broadening therapeutic options while intensifying the need for greater clinical differentiation within an increasingly granular, biomarker-driven landscape.

Questions answered

• What are the treatment rates for NSCLC in the various settings and lines of therapy?
• What are the rates of testing for different biomarkers, and what is the uptake of key biomarker-driven therapies?
• How are new therapy entrants to the NSCLC market performing relative to existing therapies?
• What do surveyed physicians consider the main drivers of and key obstacles to the uptake of select therapies?

Product description

Through survey data from U.S. physicians, Current Treatment: Physician Insights offers in-depth analyses of the reasons behind treatment dynamics, prescribing behavior, and brand preference, enabling you to:

• Understand the treatment landscape for a disease and how physicians make prescribing decisions.
• Evaluate the drivers and obstacles that influence treatment selection.
• Analyze your brand’s performance from the physician perspective to enhance or defend your competitive position.
• Create impactful messaging for physicians by identifying brand differentiators and understanding what motivates prescribing behaviors.

Primary research: Survey of 100 U.S. medical oncologists

Key drugs covered: Alecensa, Cyramza, Datroway, Imfinzi, Imjudo, Keytruda, Keytruda Qlex, Krazati, Lazcluze, Libtayo, Lorbrena, Lumakras, Opdivo, Opdivo Qvantig, Retevmo, Rybrevant, Tagrisso, Tecentriq, Tecentriq Hybreza, Yervoy, Zegfrovy